Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 12/20 | 0.72 |
| ▸ | NNMT | P40261 | 3/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.44 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30403146 | 0.84 | HCAR3 (1.00) | HCAR3NNMTHCAR2 | |
| SCHEMBL185895 | 0.84 | HCAR3 (1.00) | HCAR3NNMTHCAR2 | |
| SCHEMBL18715411 | 0.82 | HCAR3 (0.70) | HCAR3NNMTMAPT | |
| SCHEMBL7093993 | 0.82 | PTK2 (0.62) | HCAR3NNMTMAPTKMT2A | |
| SCHEMBL11005841 | 0.82 | NNMT (0.53) | HCAR3NNMTMAPTHCAR2KCNJ1 | |
| Hydrochloric Acid SCHEMBL4035906 | 0.82 | HCAR3 (0.96) | HCAR3NNMTHCAR2 | |
| SCHEMBL4320704 | 0.82 | NNMT (1.00) | HCAR3NNMT | |
| Hydrochloric Acid SCHEMBL6474495 | 0.82 | HCAR3 (0.96) | HCAR3NNMTHCAR2 | |
| SCHEMBL8590143 | 0.81 | HCAR3 (0.53) | HCAR3NNMTMAPTHCAR2 | |
| SCHEMBL6984008 | 0.81 | HCAR3 (0.68) | HCAR3NNMTMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151517-A1 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS ASSOCIATED WITH MISSFOLDING OF ALPHA-SYNUCLEIN PROTEIN | WAVEBREAK THERAPEUTICS LIMITED (US) | 2025-07-17 | — | — | WO | disclosed |
| US-20230285569-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF FRAGILE X | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-10717738-B2 | Pyrimidinone and its derivatives inhibiting factor XIa | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-07-21 | — | — | US | disclosed |
| EP-2870156-B1 | PYRIMIDINONE DERIVATIVES AS ANTIMALARIAL AGENTS | SANOFI SA (FR) | 2020-06-17 | — | — | EP | disclosed |
| EP-3290413-B9 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2020-04-29 | — | — | EP | disclosed |
| EP-3290413-B1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2019-11-13 | — | — | EP | disclosed |
| EP-3290413-A1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO Pharmaceutical Co., Ltd. (JP) | 2018-03-07 | — | — | EP | disclosed |
| EP-2794597-B1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2017-11-15 | — | — | EP | disclosed |
| US-20170305917-A1 | COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-10-26 | — | — | US | disclosed |
| US-9732085-B2 | Pyridinone and pyrimidinone derivatives as factor Xia | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-08-15 | — | — | US | disclosed |
| US-9321790-B2 | Pyrimidinone derivatives as antimalarial agents | SANOFI (FR) | 2016-04-26 | — | — | US | disclosed |
| US-9321790-B2 | Pyrimidinone derivatives as antimalarial agents | SANOFI (FR) | 2016-04-26 | — | — | US | disclosed |
| US-20150183804-A1 | Pyrimidinone Derivatives as Antimalarial Agents | SANOFI (FR) | 2015-07-02 | — | — | US | disclosed |
| US-20150183804-A1 | Pyrimidinone Derivatives as Antimalarial Agents | SANOFI (FR) | 2015-07-02 | — | — | US | disclosed |
| US-20150152112-A1 | COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-06-04 | — | — | US | disclosed |
| US-7956052-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-07 | — | — | US | disclosed |
| US-20100087435-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-08 | — | — | US | disclosed |
| US-7659268-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-02-09 | — | — | US | disclosed |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-24 | — | — | US | disclosed |
| EP-1816136-A1 | GPR7-SELECTIVE LIGAND AND USE THEREOF | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087435-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | HCAR3 1332/4885NNMT 1349/4885MAPT 4509/4885 |
| US-20150152112-A1 | COMPOUNDS | F11, F12, F10 | HCAR3 3121/4885NNMT 1800/4885MAPT 4558/4885 |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | CFTR, ABCC8, ABCB1 | HCAR3 2092/4885NNMT 1296/4885MAPT 4668/4885 |
| US-20150183804-A1 | Pyrimidinone Derivatives as Antimalarial Agents | DHFR, PRMT1, PRMT7 | HCAR3 4490/4885NNMT 28/4885MAPT 2806/4885 |
| US-20170305917-A1 | COMPOUNDS | F11, F12, F10 | HCAR3 3121/4885NNMT 1800/4885MAPT 4558/4885 |
| US-20230285569-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF FRAGILE X | CYFIP2, TPX2, CYFIP1 | HCAR3 1528/4885NNMT 1370/4885MAPT 2699/4885 |
| US-10717738-B2 | Pyrimidinone and its derivatives inhibiting factor XIa | F11, TFPI, F10 | HCAR3 4085/4885NNMT 1032/4885MAPT 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.